Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
35.70
+1.41 (4.11%)
Apr 15, 2026, 3:04 PM CST
SHE:002422 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 17,864 | 21,107 | 20,714 | 18,601 | 16,936 |
Other Revenue | 648.53 | 705.65 | 739.64 | 437.62 | 341.23 |
| 18,513 | 21,812 | 21,454 | 19,038 | 17,277 | |
Revenue Growth (YoY) | -15.13% | 1.67% | 12.69% | 10.19% | 4.94% |
Cost of Revenue | 9,767 | 10,613 | 10,291 | 9,084 | 7,993 |
Gross Profit | 8,746 | 11,200 | 11,163 | 9,954 | 9,284 |
Selling, General & Admin | 4,246 | 4,801 | 5,592 | 5,657 | 5,877 |
Research & Development | 2,205 | 2,171 | 1,944 | 1,795 | 1,737 |
Other Operating Expenses | 154.79 | 110.88 | 184.61 | 192.45 | 150.4 |
Operating Expenses | 6,641 | 7,156 | 7,756 | 7,694 | 7,800 |
Operating Income | 2,105 | 4,044 | 3,407 | 2,260 | 1,484 |
Interest Expense | -102.84 | -151.62 | -361.54 | -475.22 | -518.34 |
Interest & Investment Income | 291.83 | 416.62 | 462.47 | 278.81 | 244.03 |
Currency Exchange Gain (Loss) | -45.57 | 16.89 | 33.36 | -41.86 | -2.31 |
Other Non Operating Income (Expenses) | 2.32 | -170.39 | -18.95 | -143.9 | -21.84 |
EBT Excluding Unusual Items | 2,251 | 4,155 | 3,522 | 1,878 | 1,186 |
Impairment of Goodwill | -2.41 | - | - | - | - |
Gain (Loss) on Sale of Investments | 27.61 | 19.9 | 14.67 | 9.86 | 4.83 |
Gain (Loss) on Sale of Assets | 5.32 | 0.81 | 2.63 | 5.4 | -7.94 |
Asset Writedown | -13.03 | -65.85 | -58.62 | -1.93 | -13.2 |
Legal Settlements | 73.41 | - | - | - | - |
Other Unusual Items | 62.08 | 175.04 | 99.62 | 177 | 8.38 |
Pretax Income | 2,404 | 4,285 | 3,580 | 2,068 | 1,178 |
Income Tax Expense | 526.62 | 923.4 | 933.79 | 363.7 | 309.5 |
Earnings From Continuing Operations | 1,877 | 3,362 | 2,647 | 1,704 | 868.12 |
Minority Interest in Earnings | -175.28 | -426.06 | -190.53 | 1.1 | 234.44 |
Net Income | 1,702 | 2,936 | 2,456 | 1,705 | 1,103 |
Net Income to Common | 1,702 | 2,936 | 2,456 | 1,705 | 1,103 |
Net Income Growth | -42.03% | 19.53% | 44.03% | 54.67% | 32.94% |
Shares Outstanding (Basic) | 1,591 | 1,578 | 1,453 | 1,398 | 1,414 |
Shares Outstanding (Diluted) | 1,591 | 1,578 | 1,545 | 1,483 | 1,414 |
Shares Change (YoY) | 0.77% | 2.18% | 4.17% | 4.91% | -1.15% |
EPS (Basic) | 1.07 | 1.86 | 1.69 | 1.22 | 0.78 |
EPS (Diluted) | 1.07 | 1.86 | 1.59 | 1.15 | 0.78 |
EPS Growth | -42.47% | 16.98% | 38.26% | 47.44% | 34.48% |
Free Cash Flow | 1,020 | 2,815 | 3,568 | 2,230 | 1,857 |
Free Cash Flow Per Share | 0.64 | 1.78 | 2.31 | 1.50 | 1.31 |
Dividend Per Share | 0.594 | 0.763 | 0.800 | 0.616 | 0.426 |
Dividend Growth | -22.15% | -4.63% | 29.87% | 44.60% | 33.63% |
Gross Margin | 47.24% | 51.35% | 52.03% | 52.29% | 53.74% |
Operating Margin | 11.37% | 18.54% | 15.88% | 11.87% | 8.59% |
Profit Margin | 9.19% | 13.46% | 11.45% | 8.96% | 6.38% |
Free Cash Flow Margin | 5.51% | 12.90% | 16.63% | 11.71% | 10.75% |
EBITDA | 3,397 | 5,249 | 4,596 | 3,416 | 2,690 |
EBITDA Margin | 18.35% | 24.06% | 21.42% | 17.94% | 15.57% |
D&A For EBITDA | 1,292 | 1,205 | 1,189 | 1,156 | 1,206 |
EBIT | 2,105 | 4,044 | 3,407 | 2,260 | 1,484 |
EBIT Margin | 11.37% | 18.54% | 15.88% | 11.87% | 8.59% |
Effective Tax Rate | 21.91% | 21.55% | 26.08% | 17.59% | 26.28% |
Revenue as Reported | 18,513 | 21,812 | 21,454 | 19,038 | 17,277 |
Advertising Expenses | 25.09 | 145.44 | 265.58 | 129.59 | 161.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.